Home LiteratureArticle Details
PMID: 17021801 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes.

Pflugers Archiv : European journal of physiology ·Vol. 453 ·No. 3 ·2006-12-00 ·Pages 323-32

Girard CA, Shimomura K, Proks P, Absalom N, Castano L, Perez de Nanclares G, Ashcroft FM

Abstract

ATP-sensitive potassium (K(ATP)) channels, composed of pore-forming Kir6.2 and regulatory sulphonylurea receptor (SUR) subunits, play an essential role in insulin secretion from pancreatic beta cells. Binding of ATP to Kir6.2 inhibits, whereas interaction of Mg-nucleotides with SUR, activates the channel. Heterozygous activating mutations in Kir6.2 (KCNJ11) are a common cause of neonatal diabetes (ND). We assessed the functional effects of six novel Kir6.2 mutations associated with ND: H46Y, N48D, E227K, E229K, E292G, and V252A. K(ATP) channels were expressed in Xenopus oocytes and the heterozygous state was simulated by coexpression of wild-type and mutant Kir6.2 with SUR1 (the beta cell type of SUR). All mutations reduced the sensitivity of the K(ATP) channel to inhibition by MgATP, and enhanced whole-cell K(ATP) currents. Two mutations (E227K, E229K) also enhanced the intrinsic open probability of the channel, thereby indirectly reducing the channel ATP sensitivity. The other four mutations lie close to the predicted ATP-binding site and thus may affect ATP binding. In pancreatic beta cells, an increase in the K(ATP) current is expected to reduce insulin secretion and thereby cause diabetes. None of the mutations substantially affected the sensitivity of the channel to inhibition by the sulphonylurea tolbutamide, suggesting patients carrying these mutations may respond to these drugs.

MeSH Terms
ATP-Binding Cassette Transporters/genetics,physiology Adenosine Triphosphate/physiology Animals Diabetes Mellitus/genetics,physiopathology Female Genotype Humans Hypoglycemic Agents/pharmacology Infant Infant, Newborn Insulin-Secreting Cells/physiology Multidrug Resistance-Associated Proteins/genetics,physiology Mutation/genetics Patch-Clamp Techniques Potassium Channels, Inwardly Rectifying/drug effects,genetics,physiology Rats Receptors, Drug Sulfonylurea Receptors Tolbutamide/pharmacology Transfection Xenopus laevis
Chemicals
ABCC8 protein, human ATP-Binding Cassette Transporters Abcc8 protein, rat Hypoglycemic Agents Kir6.2 channel Multidrug Resistance-Associated Proteins Potassium Channels, Inwardly Rectifying Receptors, Drug Sulfonylurea Receptors Adenosine Triphosphate Tolbutamide
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Girard Christophe A J
University Laboratory of Physiology, Oxford University, Oxford, OX1 3PT, UK. [email protected]
Shimomura Kenju
Proks Peter
Absalom Nathan
Castano Luis
Perez de Nanclares Guiomar
Ashcroft Frances M
References (43)
43 references, click to expand
  1. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
    N Engl J Med. 2004 Apr 29;350(18):1838-49 PMID: 15115830
  2. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.
    Pflugers Arch. 1981 Aug;391(2):85-100 PMID: 6270629
  3. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle.
    FEBS Lett. 1995 Dec 27;377(3):338-44 PMID: 8549751
  4. Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification.
    Nat Neurosci. 2005 Mar;8(3):279-87 PMID: 15723059
  5. ATP interaction with the open state of the K(ATP) channel.
    Biophys J. 2001 Feb;80(2):719-28 PMID: 11159439
  6. Molecular mechanism for ATP-dependent closure of the K+ channel Kir6.2.
    J Physiol. 2003 Oct 1;552(Pt 1):23-34 PMID: 12860923
  7. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes.
    Diabetes. 2000 Aug;49(8):1359-66 PMID: 10923638
  8. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes.
    Cell. 2000 Mar 17;100(6):645-54 PMID: 10761930
  9. MgATP activates the beta cell KATP channel by interaction with its SUR1 subunit.
    Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7185-90 PMID: 9618560
  10. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
    J Clin Endocrinol Metab. 2004 Nov;89(11):5504-7 PMID: 15531505
  11. A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome.
    EMBO Rep. 2005 May;6(5):470-5 PMID: 15864298
  12. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.
    Science. 1995 Nov 17;270(5239):1166-70 PMID: 7502040
  13. Kir6.2 mutations causing neonatal diabetes provide new insights into Kir6.2-SUR1 interactions.
    EMBO J. 2005 Jul 6;24(13):2318-30 PMID: 15962003
  14. ATP sensitivity of ATP-sensitive K+ channels: role of the gamma phosphate group of ATP and the R50 residue of mouse Kir6.2.
    J Physiol. 2005 Nov 1;568(Pt 3):931-40 PMID: 16166157
  15. Adenosine diphosphate as an intracellular regulator of insulin secretion.
    Science. 1996 Jun 21;272(5269):1785-7 PMID: 8650576
  16. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes.
    Hum Mutat. 2005 Jan;25(1):22-7 PMID: 15580558
  17. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    N Engl J Med. 2006 Aug 3;355(5):467-77 PMID: 16885550
  18. Relapsing diabetes can result from moderately activating mutations in KCNJ11.
    Hum Mol Genet. 2005 Apr 1;14(7):925-34 PMID: 15718250
  19. Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects.
    Diabetes. 2006 Jun;55(6):1705-12 PMID: 16731833
  20. Sulphonylurea action revisited: the post-cloning era.
    Diabetologia. 2003 Jul;46(7):875-91 PMID: 12819907
  21. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy.
    Diabetes. 2005 Sep;54(9):2503-13 PMID: 16123337
  22. From molecule to malady.
    Nature. 2006 Mar 23;440(7083):440-7 PMID: 16554803
  23. Octameric stoichiometry of the KATP channel complex.
    J Gen Physiol. 1997 Dec;110(6):655-64 PMID: 9382894
  24. Stabilization of the activity of ATP-sensitive potassium channels by ion pairs formed between adjacent Kir6.2 subunits.
    J Gen Physiol. 2003 Aug;122(2):225-37 PMID: 12885877
  25. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.
    Diabetes. 2004 Oct;53(10):2713-8 PMID: 15448106
  26. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Diabetes. 2006 Jun;55(6):1731-7 PMID: 16731836
  27. Crystal structure of the potassium channel KirBac1.1 in the closed state.
    Science. 2003 Jun 20;300(5627):1922-6 PMID: 12738871
  28. Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP.
    Hum Mol Genet. 2005 Sep 15;14(18):2717-26 PMID: 16087682
  29. Neonatal diabetes: new insights into aetiology and implications.
    Horm Res. 2000;53 Suppl 1:7-11 PMID: 10895036
  30. Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit.
    EMBO J. 2005 Jan 26;24(2):229-39 PMID: 15650751
  31. Type 2 diabetes mellitus: not quite exciting enough?
    Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R21-31 PMID: 14734629
  32. The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus.
    J Clin Endocrinol Metab. 2005 Jun;90(6):3174-8 PMID: 15784703
  33. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
    Hum Mol Genet. 2006 Jun 1;15(11):1793-800 PMID: 16613899
  34. Properties of cloned ATP-sensitive K+ currents expressed in Xenopus oocytes.
    J Physiol. 1997 Jan 1;498 ( Pt 1):87-98 PMID: 9023770
  35. 3-D structural and functional characterization of the purified KATP channel complex Kir6.2-SUR1.
    EMBO J. 2005 Dec 7;24(23):4166-75 PMID: 16308567
  36. Involvement of the N-terminus of Kir6.2 in the inhibition of the KATP channel by ATP.
    J Physiol. 1999 Jan 1;514 ( Pt 1):19-25 PMID: 9831713
  37. Electrophysiology of the pancreatic beta-cell.
    Prog Biophys Mol Biol. 1989;54(2):87-143 PMID: 2484976
  38. Molecular analysis of ATP-sensitive K channel gating and implications for channel inhibition by ATP.
    J Gen Physiol. 1998 Sep;112(3):333-49 PMID: 9725893
  39. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients.
    Diabetes. 2004 Oct;53(10):2719-22 PMID: 15448107
  40. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features.
    Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17539-44 PMID: 15583126
  41. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells.
    Nature. 1984 Nov 29-Dec 5;312(5993):446-8 PMID: 6095103
  42. ATP-sensitive potassium channelopathies: focus on insulin secretion.
    J Clin Invest. 2005 Aug;115(8):2047-58 PMID: 16075046
  43. Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor.
    Nature. 1997 May 8;387(6629):179-83 PMID: 9144288
Article Info
Journal
Pflugers Archiv : European journal of physiology
Abbr.
Pflugers Arch
ISSN
0031-6768
Published
2006-12-00
Epub
2006-00-22
Pages
323-32
Language
English
Region
Germany
NLM ID
0154720
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]